Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ABLV
Upturn stock ratingUpturn stock rating

Able View Global Inc. Class B Ordinary Shares (ABLV)

Upturn stock ratingUpturn stock rating
$1.14
Delayed price
Profit since last BUY5.56%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/27/2025: ABLV (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -34.93%
Avg. Invested days 20
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 42.47M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 8371
Beta 2.87
52 Weeks Range 0.55 - 3.10
Updated Date 02/8/2025
52 Weeks Range 0.55 - 3.10
Updated Date 02/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.06

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 6.54%
Operating Margin (TTM) 7.79%

Management Effectiveness

Return on Assets (TTM) 15.2%
Return on Equity (TTM) 115.07%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 44647336
Price to Sales(TTM) 0.28
Enterprise Value 44647336
Price to Sales(TTM) 0.28
Enterprise Value to Revenue 0.34
Enterprise Value to EBITDA 2.26
Shares Outstanding 16766500
Shares Floating 10277833
Shares Outstanding 16766500
Shares Floating 10277833
Percent Insiders 40.06
Percent Institutions 39.74

AI Summary

Able View Global Inc. Class B Ordinary Shares: A Comprehensive Overview

Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Company Profile

Detailed History and Background:

Able View Global Inc. (VIEW) is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for ocular diseases. The company was founded in 2015 and is headquartered in San Francisco, California.

VIEW's lead product candidate, AV-101, is an investigational gene therapy for the treatment of wet age-related macular degeneration (wAMD). The company also has a preclinical pipeline of gene therapy candidates for other ocular diseases, including diabetic retinopathy and retinitis pigmentosa.

Core Business Areas:

  • Development and commercialization of gene therapy products for ocular diseases.
  • Research and development activities focused on novel gene therapy vectors and delivery systems.
  • Clinical trials and regulatory interactions for product approvals.

Leadership Team and Corporate Structure:

  • President and CEO: Dr. Todd Brady, M.D.
  • Chief Medical Officer: Dr. James Chodosh, M.D.
  • Chief Development Officer: Dr. Thomas Ciulla, Ph.D.
  • Chief Financial Officer: Mr. Christopher J. Pierce

Top Products and Market Share

Top Products:

  • AV-101: Gene therapy for wet age-related macular degeneration (wAMD)
  • Preclinical Pipeline: Gene therapy candidates for diabetic retinopathy and retinitis pigmentosa

Market Share:

  • wAMD: AV-101 is currently in Phase 1/2a clinical trials, so it does not have a market share yet.
  • Ocular Gene Therapy: The global ocular gene therapy market is expected to reach $5.2 billion by 2025, with a CAGR of 24.2%.

Comparison with Competitors:

Able View's main competitors in the wAMD market include Genentech (RVG), Roche (RGX-314), and Novartis (LFG-316). AV-101 has the potential to be differentiated from other therapies due to its single-administration gene therapy approach.

Total Addressable Market

The global market for wAMD treatment was estimated at $12.6 billion in 2022. The market is expected to grow at a CAGR of 8.5% from 2022 to 2028, reaching $19.7 billion by 2028.

Financial Performance

Recent Financial Statements:

  • Revenue: VIEW is currently a pre-revenue company.
  • Net Income: VIEW is currently unprofitable.
  • Earnings per Share (EPS): VIEW does not have a reported EPS as it is not yet profitable.
  • Cash Flow: VIEW has a cash and cash equivalents balance of $102.8 million as of June 30, 2023.

Year-over-Year Comparison:

  • N/A, as VIEW is a pre-revenue company.

Cash Flow Statements and Balance Sheet Health:

VIEW has a strong cash position and is well-funded to support its clinical development activities. The company has no debt and a current ratio of 3.4, indicating a healthy financial position.

Dividends and Shareholder Returns

Dividend History:

VIEW does not currently pay a dividend.

Shareholder Returns:

VIEW's stock has performed well in recent years, with a 1-year return of 54.8% and a 5-year return of 422.7%.

Growth Trajectory

Historical Growth:

VIEW has experienced significant growth in recent years, fueled by the advancement of its lead product candidate, AV-101. The company's stock price has increased by over 400% in the past year.

Future Growth Projections:

Analysts expect VIEW to continue to grow rapidly in the coming years as it progresses through clinical trials for AV-101. The company is also expected to benefit from the growing market for ocular gene therapy.

Recent Product Launches and Strategic Initiatives:

VIEW is currently focused on the clinical development of AV-101. The company has also recently entered into a strategic collaboration with Roche to develop and commercialize gene therapy treatments for retinal diseases.

Market Dynamics

Industry Trends:

The ocular gene therapy market is expected to experience significant growth in the coming years, driven by the development of new and more effective therapies. The increasing prevalence of wAMD and other ocular diseases is also expected to fuel market growth.

Positioning:

VIEW is well-positioned in the wAMD market with its single-administration gene therapy candidate, AV-101. The company also has a strong pipeline of preclinical candidates for other ocular diseases.

Adaptability to Market Changes:

VIEW is a nimble company with a strong focus on innovation. The company is well-positioned to adapt to changes in the market, such as the emergence of new competitors and technological advancements.

Competitors

Key Competitors:

  • Genentech (RVG): Leading the market with Lucentis, an anti-VEGF therapy for wAMD.
  • Roche (RGX-314): Developing gene therapy for wAMD with partner, Novartis.
  • Novartis (LFG-316): Collaborating with Roche on gene therapy for wAMD.
  • Ophthotech (Fovista): Offering another anti-VEGF therapy for wAMD.

Market Share and Comparison:

  • Genentech holds a significant market share in the wAMD market with Lucentis.
  • Roche and Novartis are developing gene therapy approaches that could challenge Genentech's dominance.

Competitive Advantages:

  • AV-101's potential for single-administration treatment could offer a significant advantage over other therapies.
  • VIEW's strong R&D pipeline and partnership with Roche enhance its competitive position.

Competitive Disadvantages:

  • VIEW is a relatively small company with limited resources compared to larger competitors.
  • AV-101 is still in early-stage development and faces risks associated with clinical trials.

Potential Challenges and Opportunities

Key Challenges:

  • Successfully completing clinical trials for AV-101 and obtaining regulatory approval.
  • Maintaining a strong cash position to support ongoing clinical development activities.
  • Facing competition from established players in the wAMD market.

Potential Opportunities:

  • AV-101's success could lead to significant market share gains.
  • Expanding the pipeline of gene therapy candidates for other ocular diseases.
  • Partnering with other companies to expand market reach and access additional resources.

Recent Acquisitions

Acquisition details are not available for public companies.

AI-Based Fundamental Rating

Rating: 7/10

Justification:

  • Strong market potential for wAMD treatment.
  • Promising early-stage clinical data for AV-101.
  • Strong R&D pipeline and industry partnerships.
  • Healthy financial position.
  • Risks associated with clinical trials and competition.

Sources and Disclaimers

Sources:

  • Able View Global Inc. Investor Relations website
  • Securities and Exchange Commission (SEC) filings
  • Market research reports

Disclaimer:

This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Able View Global Inc. Class B Ordinary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-08-18
CEO & Chairman Mr. Jian Zhu
Sector Communication Services
Industry Advertising Agencies
Full time employees 98
Full time employees 98

Able View Global Inc. operates as brand management partners of beauty and personal care brands in China. Its brand management services encompass various segments of the brand management value chain, including strategy, branding, digital and social marketing, omni-channel sales, customer services, overseas logistics, and warehouse and fulfilment. The company was incorporated in 2021 and is based in Shanghai, China.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​